Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Gastric Ulcers Overview | 6 | 1 |
| Therapeutics Development | 7 | 1 |
| Pipeline Products for Gastric Ulcers Overview | 7 | 1 |
| Gastric Ulcers Therapeutics under Development by Companies | 8 | 1 |
| Gastric Ulcers Pipeline Products Glance | 9 | 2 |
| Clinical Stage Products | 9 | 1 |
| Early Stage Products | 10 | 1 |
| Gastric Ulcers Products under Development by Companies | 11 | 1 |
| Gastric Ulcers Companies Involved in Therapeutics Development | 12 | 5 |
| Ache Laboratorios Farmaceuticos S/A | 12 | 1 |
| Astellas Pharma Inc. | 13 | 1 |
| ChoDang Pharm Co., Ltd. | 14 | 1 |
| Kukje Pharmaceutical Industry Co., Ltd. | 15 | 1 |
| XuanZhu Pharma Co., Ltd. | 16 | 1 |
| Gastric Ulcers Therapeutics Assessment | 17 | 8 |
| Assessment by Monotherapy Products | 17 | 1 |
| Assessment by Combination Products | 18 | 1 |
| Assessment by Target | 19 | 2 |
| Assessment by Mechanism of Action | 21 | 2 |
| Assessment by Route of Administration | 23 | 1 |
| Assessment by Molecule Type | 24 | 1 |
| Drug Profiles | 25 | 7 |
| (ecabet + ranitidine) Drug Profile | 25 | 1 |
| anaprazole sodium Drug Profile | 26 | 1 |
| ASP-6537 Drug Profile | 27 | 1 |
| KJ-14001 Drug Profile | 28 | 1 |
| PDI-39 Drug Profile | 29 | 1 |
| PMKS-005 Drug Profile | 30 | 1 |
| Small Molecules for Gastric Ulcers Drug Profile | 31 | 1 |
| Gastric Ulcers Dormant Projects | 32 | 1 |
| Gastric Ulcers Discontinued Products | 33 | 1 |
| Gastric Ulcers Product Development Milestones | 34 | 8 |
| Featured News &Press Releases | 34 | 1 |
| Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies | 34 | 1 |
| Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck | 35 | 1 |
| Jan 07, 2010: AstraZeneca Reaches Agreements with Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations | 35 | 1 |
| Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy | 35 | 1 |
| Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck &Co., Inc. | 36 | 1 |
| Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium) | 37 | 1 |
| Jun 01, 2007: AstraZeneca s Prilosec Patents Upheld By Court | 37 | 1 |
| Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court | 38 | 1 |
| Aug 08, 2003: Astrazeneca to Seek Triple Damages in Patent Infringement Lawsuit Against Mylan Pharmaceuticals | 38 | 1 |
| Oct 23, 2001: Prilosec US litigation | 39 | 1 |
| May 02, 2001: Astrazeneca Receives Six Months' Market Exclusivity for Prilosec | 39 | 1 |
| May 02, 2001: Court Denies Generic's Application for Summary Judgement on Prilosec Patent | 39 | 1 |
| Apr 23, 2001: Astrazeneca Files Lawsuit Against Apotex Corporation and Torpharm for Patent Infringement | 39 | 1 |
| Dec 19, 2000: Astrazeneca Wins Losec Patent Litigation in Canada | 40 | 1 |
| Oct 20, 2000: Joint FDA Advisory Committee Confirms OTC Prilosec (Omeprazole) Safety and Efficacy | 40 | 2 |
| Appendix | 42 | 2 |
| Methodology | 42 | 1 |
| Coverage | 42 | 1 |
| Secondary Research | 42 | 1 |
| Primary Research | 42 | 1 |
| Expert Panel Validation | 42 | 1 |
| Contact Us | 42 | 1 |
| Disclaimer | 43 | 1 |